Long Term Documentation of the Safety and Efficacy as Well as the Effects on Quality of Life and Work Productivity in Patients With Rheumatoid Arthritis Under HUMIRA® (Adalimumab) in Routine Clinical Practice (AGIL)
Phase of Trial: Phase IV
Latest Information Update: 12 Apr 2017
At a glance
- Drugs Adalimumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- Acronyms AGIL
- Sponsors AbbVie
- 07 Jun 2017 Biomarkers information updated
- 07 Apr 2017 Planned End Date changed from 1 May 2018 to 1 Aug 2017.
- 07 Apr 2017 Planned primary completion date changed from 1 May 2018 to 1 Aug 2017.